Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI2006245 |
Pages: NA |
Jan 2023 |
Tissue diagnostics is a complete understanding and documenting about a tissue that was obtained. Also, it can be defined as a tissue collected for diagnosing and observing its overall measurement and description and observing if any abnormality exists. With the use of tissue diagnostics, we can know the status of a patient’s health condition and any diseased state. It can be conducted through mail processes like scanning, slide staining, in situ hybridization (ISH), and other techniques.
The tissue diagnostics is most fundamentally utilized for lymphoma, breast cancer, carcinoma, prostate malignant growth, and gastric malignant growth. Among these, breast cancer is dominating the tissue diagnostics market attributable to rising oncological conditions in developed and developing nations. As indicated by the World Health Organization, 2.1 million people acquire breast cancer every year, and 627,000 have demised out of the breast cancer, in 2018.
An increase in the number of cancer conditions globally, which is causing the need for better features, and advanced technology will drive the market in the estimated period. An increase in healthcare expenditure is predicted to drive the market in the forecast period. The increased focus by the market leaders in developing advanced level tissue diagnostic-based text will drive the revenue generation in the tissue diagnostics market.
Higher cost for installing the systems and higher penetration in the developing countries is predicted to hamper the market in the forecast period. There is a strict regulatory framework for new product approval and regulations by the authorities hinder the market growth in the forecast period. Lack of awareness in rural areas, lesser accessibility for healthcare indicators in underdeveloped nations and social stigma about cancerous condition among people are the other hindrances for the development of tissue diagnostics market.
The variables, for instance, the expanding cases of cancers, expanding interests in innovative work of new advancements, development of proficient and precise items, developing interest for customized drugs, and undiscovered market potential because of the absence of productive diagnostics tests for non-small lung cancer discovery are relied upon to give potential chances to the development of tissue diagnostics market. The rising number of healthcare centres is probably going to support the interest in the tissue diagnostics market.
Immunochemistry (IHC) is the most widely used technology segment in both Clinical Research and Development for cancer treatment and therapy, resulting in the highest revenue generation in the forecast period. The preference of immunochemistry technology is increasing as it provides differentiation between various types of tumours, unlike the conventional methods, which only detect a very few numbers of tissue structures and proteins of the tumours. Digital pathology is expected to show tremendous growth in the forecast period. The growth is due to increasing usage of whole slide imaging (WSI) by pathologists. The whole slide imaging extracts characteristics of the tumour. It quantifies each element of that character, which will support the cancer diagnosis further and give information about clinical measures for treating the tumour. These aspects are predicted to boost the market in the forecast period.
The breast cancer segment is predicted to have the highest growth rate in the forecast period. Inclination in breast cancer globally and an increase in the genetic inheritance is predicted to boost the segment in the forecast period. These factors have caused serious concern among many people resulting in several research initiatives and support from the government and private centres. This will further develop this market and help in the diagnosis of breast cancer. The prostate cancer segment is predicted to have a lucrative growth in the forecast period. The progress in prostate cancer biomarker discovery and advancements in genomic technologies are predicted to boost the segment in the forecast period. Biomarker discovery has led to the development of tissue diagnostic assays and created opportunities for this segmental growth in the forecast period.
Hospitals are currently dominating in terms of its highest revenue generation. Hospitals have a higher consumption than any other end-user segment due to its utility rate of tissue diagnostic solutions. Physicians are increasingly switching to use of tissue-based diagnostic techniques from the conventional ones because of reduction in the time being consumed when compared to the traditional methods. The growth is due to the increase in agreement models being implemented by the hospitals.
Contract research organizations (CRO) are expected to witness immense growth. These are the organizations that provide research support, manage trails, clinical trial services, and functions of the companies and healthcare services that have a budget constraint. As the research studies in cancer therapy have been increasing drastically over recent years, the demand for service provided by these organizations is also increasing, which will accelerate the growth and revenue of this segment.
North America region market has the highest revenue generated in the current market condition. The demand for tissue diagnostics is expected to grow due to certain reasons like the precision medicine initiative implementation in the United States, the adoption of sequencing Technologies, healthcare IT systems, and personalized medicine. Asia-Pacific region is expected to show lucrative growth in the forecast period. Higher accessibility to tissue diagnostic assays by many international companies is predicted to boost the segment in the forecast period.
The key revenue generators in the tissue diagnostics market are Abbott Laboratories, Danaher, Siemens, Merck KGaA, GE Healthcare, Thermo Fisher Scientific Inc., bioMérieux SA, DiaGenic ASA, QIAGEN, Becton, F. Hoffmann-La Roche Ltd., Dickinson and Company, BioGenex, Bio SB, and Agilent Technologies. The market is highly competitive due to the presence of many players of different sizes.
|
Aspect |
Particulars |
|
Historical Market Estimations |
2019-2020 |
|
Base Year for Market Estimation |
2019 |
|
Forecast timeline for Market Projection |
2020-2027 |
|
Geographical Scope |
North America, Europe, Asia-Pacific, LAMEA |
|
Segmentation by Application |
|
|
Segmentation by End User |
|
|
Segmentation by Technology |
|
|
Key Countries Covered |
U.S., Germany, France, Canada Spain, China, India, Brazil, Mexico, Japan and South Africa |
|
Key Companies Profiled |
|
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization